Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis, published this April in the New England Journal of Medicine, demonstrated benefits of an investigational, once-a-day pill called brensocatib as a therapy for the chronic lung condition.
The clinical trial findings are important, as there are currently no FDA-approved medications for bronchiectasis, a chronic condition with persistent lung airway inflammation and infection….
Continue Reading
News Source: www.sciencedaily.com
Leave a Reply